Drug Coverage
Drug Coverage
Navigating Drug Formularies
Schaeffer experts evaluate trends in drug formularies and utilization restrictions to determine whether patients are getting access to high-value medicines.
Related Topics
Top Drug Coverage Stories View All
News
Pharmaceutical Spending Is Shifting Away From ‘Me-Too’ Drugs
Featured Experts: Darius Lakdawalla, Boshen Jiao
In The News View All
CalMatters
Ward discusses tension between GLP-1 long-term savings and near-term insurer costs
Featured Experts: Alison Sexton Ward
Axios
A recent historic drop in drug prices is largely driven by market forces, Joyce explains
Featured Experts: Geoffrey Joyce
Healthcare Brew
Despite recent reforms, Joyce says PBMs may simply adapt business practices to generate revenue
Featured Experts: Geoffrey Joyce
Pink Sheet
Chen warns MFN could have unintended consequences and highlights need for US value-based pricing
Featured Experts: Alice Chen
MinnPost
Mulligan explains how 340B program encourages hospitals to favor more expensive drugs
Featured Experts: Karen Mulligan
Featured Perspective
A Missed Chance to Make America Healthier and Richer
Medicare should revisit its decision not to broadly cover anti-obesity medications, considering the enormous value expanded access would generate for society.
Experts: Alison Sexton Ward, Dana Goldman
Drug Coverage
Experts
Featured Research
Medicare Part D Plans Increased Restrictions on Drug Coverage
Medicare Part D plans excluded more compounds from coverage or subjected more of them to review before patients can access treatments, USC researchers found.
Experts: Geoffrey Joyce, Karen Van Nuys
